Fig. 1 · Structure

Documents & Downloads

Arecoline hydrobromide

Cat. No. A11815 CAS 300-08-3

nAChR/mAChR Agonist

Arecoline hydrobromide is a partial agonist of nicotinic (nAChR) and muscarinic acetylcholine receptors (mAChR). This naturally occurring psychoactive alkaloid possesses brain-penetrant properties and is known for its stimulation, alertness enhancement, anxiolytic effects, and anti-parasitic activity. Additionally, Arecoline hydrobromide can induce oxidative stress, making it valuable for research in neuropharmacology and related fields.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Arecoline hydrobromide Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Arecoline hydrobromide from 3 published references. In vitro models include TM4 cells; cells expressing HS α4β2 receptors.

Arecoline hydrobromide In Vitro Studies

Arecoline hydrobromide treatment reduced insoluble ZO-1 levels in TM4 cells compared with mock control. In cells expressing HS α4β2 receptors, a design using Arecoline and including ACh and atropine showed reduced responses to a control application of ACh relative to initial control responses to ACh. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Insoluble junctional protein levels in cells

Cell-based study · TM4 cells [1]

TM4 cells received Arecoline hydrobromide at 200 and 400 μM for 6 hours. Insoluble ZO-1 levels fell to 74.7 ± 7.2% and 42.5 ± 10.7%, respectively, compared with mock control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Signals of insoluble ZO-1 were quantified by densitometry analysisinsoluble ZO-1 74.7 ± 7.2% and 42.5 ± 10.7%[1]

Literature-Reported Treatment Conditions

Treatment concentration
200 and 400 μM
Exposure duration
6 hours
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Arecoline hydrobromide; Compound label in the paper: Arecoline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Arecoline induces redistribution of ZO-1 directly (S37, S48); Figure 1 legend (S101, S108)

Signals of insoluble ZO-1 were quantified by densitometry analysis: Signals of insoluble ZO-1 were quantified by densitometry analysis; comparator: mock control — Results > Arecoline induces redistribution of ZO-1 directly (S48); Figure 1 legend (S108)

Control ACh responses in receptor-expressing cells

Cell-based study · cells expressing HS α4β2 receptors [2]

Cells expressing HS α4β2 receptors received Arecoline at 3 μM under steady flow in a design also including ACh and atropine. After 8 minutes, responses to a control application of ACh were reduced approximately 50% relative to initial control responses to ACh.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
responses to a control application of AChACh response reduced approximately 50%[2]

Literature-Reported Treatment Conditions

Treatment concentration
3 μM
Exposure duration
After 8 minutes
Method
a steady flow
Vehicle
Ringer's solution
Co-treatment
Other interventions in this design: ACh 30 μM; atropine 1 μM. Compound effect isolated by the comparison: initial control responses to ACh.
Methods and source locations

Compound reported in the paper: Arecoline

The paper names Arecoline without stating the salt or form; not verified as the hydrobromide form supplied as A11815. No dose conversion or lot validation.

Materials and Methods > Commercial reagents (S3); Materials and Methods > Two-electrode voltage clamp electrophysiology (S25, S31); Results (S82); Fig 8 legend (S124, S125)

responses to a control application of ACh: responses to a control application of ACh; comparator: initial control responses to ACh — Fig 8 legend (S125)

Arecoline hydrobromide In Vivo Studies

Adult male and female mice received Arecoline hydrobromide in drinking water ad libitum for 2 weeks. Mechanical nociceptive thresholds increased relative to water-drinking controls. [3]

Mechanical nociceptive thresholds in mice

Animal study · Adult male and female C57BL/6 mice (7–9 weeks old); naive mice; n = 11 for arecoline-drinking group, n = 11 for the water-drinking group [3]

Adult male and female mice received Arecoline hydrobromide in drinking water ad libitum for 2 weeks. Mechanical nociceptive thresholds increased to 0.47 ± 0.04 g, compared with 0.31 ± 0.05 g in water-drinking controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mechanical nociceptive thresholdmechanical nociceptive threshold 0.47 ± 0.04 g[3]

Conditions shared by the study groups

Route
drinking water
Treatment course
ad libtum for 2 weeks
Vehicle
sterile tap water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Arecoline hydrobromide 0.2%water-drinking groupDrinking arecoline increased the mechanical nociceptive threshold (Water-drinking: 0.31 ± 0.05 g vs. arecoline-drinking 0.47 ± 0.04 g, unpaired t-test, t(20) = 2.5, p = 0.02[3]
Arecoline hydrobromide 0.2%
Model: Adult male and female C57BL/6 mice (7–9 weeks old); naive mice; n = 11 for arecoline-drinking group, n = 11 for the water-drinking group
Methods and source locations

Compound reported in the paper: Arecoline hydrobromide; Compound label in the paper: Arecoline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Animal models (S5); Results > Drinking arecoline alleviates the allodynia caused by CFA injection (S69, S70, S76)

mechanical nociceptive threshold: mechanical nociceptive threshold; comparator: water-drinking group — Results > Drinking arecoline alleviates the allodynia caused by CFA injection (S70)

Arecoline hydrobromide 0.2% · Materials and methods > Animal models (S5); Results > Drinking arecoline alleviates the allodynia caused by CFA injection (S69, S70)

Specifications

Manufacturer Adooq Bioscience
Actions Partial Agonist
CAS Number 300-08-3
Applications nAChR/mAChR Agonist
Formula C8H14BrNO2
Molecular Weight 236.11
Synonyms methyl 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxylate hydrobromide
SMILES
O=C(C1=CCCN(C)C1)OC.Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Arecoline hydrobromide Research References

  1. [1] Kuo TM, Luo SY, Chiang SL, et al. Arecoline induces TNF-alpha production and Zonula Occludens-1 redistribution in mouse Sertoli TM4 cells. J Biomed Sci (2014). PMID: 25200553 DOI: 10.1186/s12929-014-0093-z Source material
  2. [2] Papke RL, Horenstein NA, Stokes C. Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity. PLoS One (2015). PMID: 26488401 DOI: 10.1371/journal.pone.0140907 Source material
  3. [3] Chen QY, Zhang Y, Ma Y, et al. Inhibition of cortical synaptic transmission, behavioral nociceptive, and anxiodepressive-like responses by arecoline in adult mice. Mol Brain (2024). PMID: 38886822 DOI: 10.1186/s13041-024-01106-5 Source material

Added to your cart

View Cart Checkout
Loading...